Rebecca Previs

Dir of Med Affairs at Labcorp Oncology; Gyn Onc; Duke adjunct. Pet mom to 🐶🐶🐱🦔🐭🐓🐝; passionate about pollination, gardening & piano. Opinions are mine.

[Vivek Subbiah, MD @VivekSubbiah]

Comprehensive Genomic Profiling: A Required Tool for Precision Oncology @ASCO @ASCOPost @OncoAlert #ASCO23 @weoncologists
https://t.co/rrSiCGXPJC

[Rebecca Previs @BeccaPrevisMD]

@VivekSubbiah presenting at #asco2023 that prior single gene testing limits the performance of CGP and negatively impacts CGP turn around time and the identification of therapeutically relevant genomic variants in #NSCLC. Performing tissue based CGP is standard of care. @Labcorp

[Outcomes4Me @outcomes4me]

One more week until our live Ask the Expert Q&A with @Labcorp's @BeccaPrevisMD! Join us to learn how #personalized #medicine is transforming #breastcancer treatment and explore emerging targeted therapies for HER2-low breast cancer subtypes: https://t.co/n7MYfPeAID

[Heidi Ko @CancerDocKo]

Want to learn more about HER2-low breast cancer? Please tune into this webinar by my amazing colleague and oncologist, Dr. @BeccaPrevisMD as she leads important discussions around HER2-low breast cancer! 🙌🏻

[Rebecca Previs @BeccaPrevisMD]

@CancerDocKo @Labcorp @OmniSeq @LabcorpDrugDev @ESeversonMDPhD Congrats @CancerDocKo and team!!👩‍⚕️🩺🧬

[Shannon Westin, MD, MPH, FASCO @ShannonWestin]

👏🙌NRG GY018!! We did it - improved progression free survival in MMRd AND MMRp #EndometrialCancer. Standard of care == CHANGED! #SGOMtg #gyncsm #ImmunoOnc Congrats to @NRGonc

[Rebecca Previs @BeccaPrevisMD]

Check out @ElizabethABloom’s work today at #SGOMtg. She reports a molecular analysis of a retrospective cohort of patients with endometrial intraepithelial hyperplasia. 5% were dMMR; 4% were p53abn. @dukeobgyn #Previslab @KC_Strickland @pammiepeters @janicewon_ 🧪🔬👩‍🔬🧬

[Rebecca Previs @BeccaPrevisMD]

Mentoring is one of life’s greatest privileges—and it’s not about creating clones but giving the space for each to create themselves and their own authentic paths. Couldn’t be prouder of @pammiepeters and @ElizabethABloom. ⭐️ 👩‍🔬🔬🧬🧪#WomenInSTEM #sgomtg #PatientsPurposeProgress

[Rebecca Previs @BeccaPrevisMD]

Checkpoint inhibition has had limited efficacy in high grade epithelial cancer. So proud of @pammiepeters and her work evaluating MEM-288, a novel oncolytic adenovirus, demonstrating efficacy and generating a systemic immune response. #SGOMtg @dukeobgyn #PatientsPurposeProgress

[Brittany Davidson @Brittdavidsonmd]

Our fellow Pamela Peters discussing her work on MEM-288 under mentor @BeccaPrevisMD proud of her work to improve the understanding of ovarian cancer immune response @dukeobgyn

[Rebecca Previs @BeccaPrevisMD]

The data are in! Cryocompression therapy works during chemo and prevents subjective neuropathy in patients with gyn cancers. Congrats @MKMontesDeOca @LHavrilesky and @dukeobgyn team. #SGOMtg #PatientsPurposeProgress

[Rebecca Previs @BeccaPrevisMD]

Thank you @Stigetta and @womenofteal for being a voice and a light. We are grateful for your advocacy, leadership, and reminding us of our purpose. #SGOMtg #PatientsPurposeProgress

[Team Ovary, Memorial Sloan Kettering Cancer Center @TeamOvary_MSK]

Standing room only for Dr. Britta Weigelt’s discussion of circulating tumor DNA! #SGO2023 @MSKPathology @SGO_org

[Rebecca Previs @BeccaPrevisMD]

Congrats to @dukeobgyn, Dr. @LHavrilesky and Dr. Haley Moss #PatientsPurposeProgress

[Rebecca Previs @BeccaPrevisMD]

Congrats to @DukeMedSchool’s @LindaM_Zambrano and her important work highlighting funding to lethality scores in patients with cancer. Despite its increase in mortality, #uterinecancer remains underfunded. This work informs policy change, advocacy and equitable funding. #sgomtg

[Rebecca Previs @BeccaPrevisMD]

#ASHKudos to @Labcorp’s @ESeversonMDPhD who presented this morning. #ASH22 @ASH_hematology 🧪🔬

[Eric Severson @ESeversonMDPhD]

Thanks to everyone who attended our @Labcorp Case Study presentation where we reviewed the clinical, morphologic, cytogenetic, and #molecular characteristics of a case with a TP53 biallelic alteration. #ASH22 @ASH_hematology

[Rebecca Previs @BeccaPrevisMD]

If you will be at the #ASH22 meeting next week, check out my @Labcorp teammate, @ESeversonMDPhD's presentation. 💜 the #ASHaiku! @ASH_hematology

[Eric Severson @ESeversonMDPhD]

Getting ready for the #ASH22 meeting with my #ASHaiku:

ASH workshop with me
December 10th, New Orleans
Hemepath with @Labcorp

@ASH_hematology

[Rebecca Previs @BeccaPrevisMD]

We analyzed ClinicalTrials,gov and found <10% of trials enrolling patients with gyn cancers report racial/ethnicity. We need diversity+transparency in enrollment. https://t.co/CPRdeot93A @tomi_akinyemiju @MKMontesDeOca @BenPeipert @dukeobgyn @DukeCancer @Labcorp @ESeversonMDPhD

[Journal of the @NCCN @JNCCN]

Healthcare Access Dimensions and Guideline-Concordant #OvarianCancer Treatment: SEER-Medicare Analysis of the ORCHiD Study: https://t.co/tdiOqBcqjj
@MKMontesdeOca @BeccaPrevisMD @anjaligupta1680 @MariaPisu1 @MLiangMD @Kevin_C_Ward @AndrewBerchuck @tomi_akinyemiju
#hsronc #GynCSM

[Rebecca Previs @BeccaPrevisMD]

Congrats @MKMontesDeOca and Dr. Tomi Akinyemiju!

[Duke Ob/Gyn @dukeobgyn]

Study finds patient’s race affects ovarian cancer care. Read more: ↙️ https://t.co/zXiDiaS9XU